Nanoparticles for Treating Brain Tumors
Author Information
Author(s): Sarin Hemant, Kanevsky Ariel S, Wu Haitao, Brimacombe Kyle R, Fung Steve H, Sousa Alioscka A, Auh Sungyoung, Wilson Colin M, Sharma Kamal, Aronova Maria A, Leapman Richard D, Griffiths Gary L, Hall Matthew D
Primary Institution: National Institutes of Health
Hypothesis
The major reason for the ineffectiveness of metal-based, lipid-based and biological-based nanoparticles in traversing the BBTB of malignant gliomas is the large size of these particles relative to the physiologic pore size of the BBTB.
Conclusion
Effective transvascular drug delivery into malignant glioma cells can be accomplished by using nanoparticles that are smaller than 11.7 to 11.9 nm in diameter and possess long blood half-lives.
Supporting Evidence
- Nanoparticles smaller than 11.7 to 11.9 nm can effectively cross the blood-brain tumor barrier.
- Long blood half-lives of nanoparticles enhance their accumulation in glioma cells.
- The study utilized dynamic contrast-enhanced MRI to measure nanoparticle transport.
Takeaway
Tiny particles can help deliver medicine to brain tumors, but they need to be small enough to get through the barriers in the brain.
Methodology
Functionalized polyamidoamine dendrimers were administered intravenously to rodents with malignant gliomas, and their transport and accumulation were measured using MRI.
Limitations
The study primarily focused on a specific type of glioma model and may not be generalizable to all types of brain tumors.
Participant Demographics
Rodents with orthotopically grown malignant gliomas.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website